Pretreatment Inflammatory Markers Predict Outcomes and Prognosis in Colorectal Cancer Patients With Synchronous Liver...

Area of Science:

• Oncology
• Clinical Biomarkers
• Cancer Prognostics

Background:

• Pretreatment inflammatory markers are used to predict colorectal cancer prognosis.
• The predictive role of these markers, particularly lymphocyte-to-monocyte ratio (LMR), in synchronous colorectal liver metastasis (CLM) survival is under-explored.
• LMR is primarily studied in hematologic malignancies.

Purpose of the Study:

• To investigate the prognostic value of pretreatment inflammatory markers for survival in patients with synchronous CLM.
• To evaluate the association of LMR and lactate dehydrogenase (LDH) with progression-free survival (PFS) and overall survival (OS) in CLM patients.

Main Methods:

• Retrospective analysis of clinical and laboratory data from 196 patients with synchronous CLM.
• Univariate and multivariate analyses were conducted to assess various inflammatory biomarkers.
• Key markers analyzed included LMR, LDH, neutrophil-to-lymphocyte ratio (NLR), and carbohydrate antigen 19-9 (CA19-9).

Main Results:

• LMR and LDH were significantly associated with PFS and OS, respectively.
• Multivariate analysis confirmed LMR as an independent predictor of PFS.
• LMR and LDH emerged as significant independent predictors for OS in CLM patients.

Conclusions:

• Elevated LMR and decreased LDH levels correlate with improved survival outcomes in synchronous CLM.
• LMR is a valuable predictor of progression-free survival.
• LMR and LDH serve as reliable biomarkers for predicting prognosis in patients with synchronous CLM.